A Phase 3, Open-label, Dose Escalation study to determine the pharmacokinetics of Atazanavir administered with RIfampicin to HIV positive adults on sEcond-line ART regimen with suppressed HIV-1 viral load (DERIVE): Scheduled Interim Analysis

Video